Compare OPTX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTX | PRQR |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.8M | 262.5M |
| IPO Year | 2021 | 2014 |
| Metric | OPTX | PRQR |
|---|---|---|
| Price | $8.99 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 293.6K | ★ 927.0K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $1.33 |
| 52 Week High | $14.92 | $3.10 |
| Indicator | OPTX | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 67.88 |
| Support Level | $6.39 | $1.40 |
| Resistance Level | $8.87 | $2.44 |
| Average True Range (ATR) | 0.68 | 0.14 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 62.22 | 80.60 |
Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining. Syntec Optics focuses on four end markets of defense, medical, consumer, and communications all with several mission-critical applications.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.